A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis

Trial Profile

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Epelsiban (Primary)
  • Indications Adenomyosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Oct 2016.
    • 06 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2016.
    • 06 Jan 2017 Status changed from suspended to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top